Orum Therapeutics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:10
Jan 22
Jan 22
Biotech tech-transfer momentum stays strong
Although Alteogen's royalty miss hurt bio sentiment, biotech moves on individual issues and technology-transfer momentum remains strong; ABL Bio, D&D Pharmatech, Orum Therapeutics, Alzinomics, and April Bio are worth watching.
MED
00:27
Jan 12
Jan 12
ORUM momentum driven by licensing hopes.
ORUM Therapeutics has the strongest bio momentum on technology export and licensing expectations, with a steady rise.
MED
12:32
Jan 05
Jan 05
Bio is next after semiconductors.
Bio is next after semiconductors; Celltrion is benefiting from biosimilar distribution and a Lilly plant acquisition, ABL Bio is the sector leader, and Orum Therapeutics’ DAC technology looks undervalued versus Aimed Bio with more upside.
HIGH
About Orum Therapeutics Investor Commentary
Across the available history and selected sources, Buzzberg tracks Orum Therapeutics across 2 sources: 2 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: Lee Yoon-hee, Kim Hyeong-cheol, Lee Jae-kyu.